title: Should statin therapy be allocated on the basis of global risk or on the basis of randomized trial evidence?
abstract: Current clinical guidelines recommend the use of a global risk assessment tool, such as those pioneered by the Framingham Heart Study, to determine eligibility for statin therapy in patients with absolute risk levels greater than a certain threshold. In support of this approach, several randomized trials have reported that patients with high absolute risk clearly benefit from statin therapy. Therefore, the guideline recommendations would seem intuitive and effective, albeit on the core assumption that the mortality and morbidity benefits associated with statin therapy would be greatest in those with high predicted absolute risk. However, if this assumption is incorrect, using predicted absolute risk to guide statin therapy could easily result in underuse in some groups and overuse in others. Herein, the authors question the utility of global risk assessment strategies based on the Framingham risk score for guiding statin therapy in light of current data that have become available from more recent and robust prospective randomized clinical trials since the publication of the National Cholesterol Education Program Adult Treatment Panel III guidelines. Moreover, the Adult Treatment Panel III guidelines do not support treatment of some patients who may benefit from statin therapy. In conclusion, the authors propose an alternative approach for incorporating more recent randomized trial data into future statin allocation algorithms and treatment guidelines.
authors.forename: Deeptankar
authors.initials: D
authors.lastname: DeMazumder
authors.forename: Rani K
authors.initials: RK
authors.lastname: Hasan
authors.forename: Roger S
authors.initials: RS
authors.lastname: Blumenthal
authors.forename: Erin D
authors.initials: ED
authors.lastname: Michos
authors.forename: Steven
authors.initials: S
authors.lastname: Jones
mesh_terms: D000465:Algorithms; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references.citation: N Engl J Med. 2005 Jul 21;353(3):238-48
references.pmid: 16034009
references.citation: J Am Coll Cardiol. 2010 Mar 23;55(12):1169-1177
references.pmid: 20298922
references.citation: N Engl J Med. 2007 Nov 29;357(22):2248-61
references.pmid: 17984166
references.citation: Lancet. 2005 Oct 8;366(9493):1267-78
references.pmid: 16214597
references.citation: JAMA. 2007 Feb 14;297(6):641-3
references.pmid: 17299201
references.citation: Circulation. 2008 Nov 25;118(22):2243-51, 4p following 2251
references.pmid: 18997194
references.citation: JAMA. 2005 Jul 20;294(3):326-33
references.pmid: 16030277
references.citation: Circulation. 2004 Jun 29;109(25 Suppl 1):IV6-19
references.pmid: 15226246
references.citation: Lancet. 2006 Sep 30;368(9542):1155-63
references.pmid: 17011942
references.citation: JAMA. 2007 Feb 14;297(6):611-9
references.pmid: 17299196
references.citation: Eur Heart J. 2010 Apr;31(7):777-83
references.pmid: 20185554
references.citation: Am J Cardiol. 2004 Jul 1;94(1):20-4
references.pmid: 15219502
references.citation: Circulation. 2009 Jan 27;119(3):382-9
references.pmid: 19139385
references.citation: N Engl J Med. 2009 Apr 2;360(14):1395-407
references.pmid: 19332456
references.citation: Circulation. 2004 Jul 13;110(2):227-39
references.pmid: 15249516
references.citation: Circulation. 2006 Feb 14;113(6):791-8
references.pmid: 16461820
references.citation: J Am Coll Cardiol. 2008 Apr 15;51(15):1512-24
references.pmid: 18402913
references.citation: J Am Coll Cardiol. 2003 May 7;41(9):1475-9
references.pmid: 12742284
references.citation: Circulation. 2010 Mar 9;121(9):1069-77
references.pmid: 20176986
references.citation: J Am Coll Cardiol. 2004 May 19;43(10):1791-6
references.pmid: 15145101
references.citation: Ann Hum Genet. 2003 Mar;67(Pt 2):97-106
references.pmid: 12675686
references.citation: N Engl J Med. 2008 Nov 20;359(21):2195-207
references.pmid: 18997196
references.citation: N Engl J Med. 2005 Apr 7;352(14):1425-35
references.pmid: 15755765
references.citation: Circulation. 2007 Aug 7;116(6):619-26
references.pmid: 17646582
references.citation: Am J Cardiol. 2007 Feb 15;99(4):535-40
references.pmid: 17293199
references.citation: Lancet. 2002 Jul 6;360(9326):7-22
references.pmid: 12114036
references.citation: Lancet. 2003 Apr 5;361(9364):1149-58
references.pmid: 12686036
references.citation: Lancet. 2008 Oct 4;372(9645):1231-9
references.pmid: 18757089
references.citation: Circulation. 2010 Jan 19;121(2):306-14
references.pmid: 20048204
references.citation: Vasc Health Risk Manag. 2009;5:1033-42
references.pmid: 20057896
references.citation: N Engl J Med. 2004 Apr 8;350(15):1495-504
references.pmid: 15007110
references.citation: Am J Cardiol. 2001 Jan 15;87(2):129-35
references.pmid: 11152826